Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 3, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

November 30, 2025

Conditions
Ovarian CancerOligometastatic DiseaseSerous Ovarian Tumor
Interventions
DRUG

Niraparib oral tablets

Niraparib 300 or 200 mg according to body weight or platelet count. Tablets will be taken orally, once daily, continuously (in 28-day cycles).

Trial Locations (13)

Unknown

RECRUITING

Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruña

RECRUITING

Hospital de Cruces, Barakaldo

RECRUITING

Hospital Universitari Vall D'Hebron, Barcelona

RECRUITING

Institut Català d' Oncologia Girona (ICO), Girona

RECRUITING

Complejo Hospitalario de Jaén, Jaén

RECRUITING

Hospital Universitario 12 de Octubre, Madrid

RECRUITING

Hospital Universitario La Paz, Madrid

RECRUITING

Hospital Universitario Ramón y Cajal, Madrid

RECRUITING

Hospital Universitario Virgen de la Victoria, Málaga

RECRUITING

Hospital Universitario Virgen Macarena, Seville

RECRUITING

Hospital Universitari Sant Joan de Reus, Tarragona

RECRUITING

Hospital Arnau de Vilanova de Valencia, Valencia

RECRUITING

Hospital Universitari i Politècnic La Fe, Valencia

All Listed Sponsors
lead

MedSIR

OTHER